Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23201900 | 1.00 | APLNR (0.51) | APLNRDPP7ALDH1A1HTR2AMEN1 | |
| SCHEMBL28622709 | 0.89 | ALDH1A1 (0.49) | APLNRDPP7ALDH1A1HTR2AMEN1 | |
| SCHEMBL29519833 | 0.87 | HSD17B10 (0.49) | APLNRDPP7ALDH1A1HTR2AMEN1 | |
| SCHEMBL20397701 | 0.85 | MEN1 (0.43) | DPP7ALDH1A1HTR2AMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL8862614 | 0.85 | HSD17B10 (0.48) | APLNRDPP7HTR2AMEN1KMT2A | |
| SCHEMBL31725864 | 0.85 | ALDH1A1 (0.41) | APLNRDPP7ALDH1A1MEN1KMT2A | |
| SCHEMBL24981985 | 0.84 | ALDH1A1 (0.47) | ALDH1A1HTR2AMEN1KMT2A | |
| SCHEMBL28989317 | 0.84 | ALDH1A1 (0.47) | ALDH1A1HTR2AMEN1KMT2A | |
| SCHEMBL20397868 | 0.84 | KIF11 (0.43) | ALDH1A1POLB | |
| SCHEMBL27665685 | 0.80 | MEN1 (0.52) | APLNRDPP7HTR2AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3805237-B1 | SYNTHESIS AND USES OF PEPTIDE BORATE ESTER COMPOUND | JIANGSU CHUANGTE PHARMACEUTICAL TECH CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-11542283-B2 | Synthesis of peptide borate ester compound and use thereof | JIANGSU CHIA TAI FENGHAI PHARMACEUTICAL CO., LTD. (CN) | 2023-01-03 | — | — | US | disclosed |
| US-11542283-B2 | Synthesis of peptide borate ester compound and use thereof | JIANGSU CHIA TAI FENGHAI PHARMACEUTICAL CO., LTD. (CN) | 2023-01-03 | — | — | US | disclosed |
| US-20210214377-A1 | SYNTHESIS OF PEPTIDE BORATE ESTER COMPOUND AND USE THEREOF | JIANGSU CHIA TAI FENGHAI PHARMACEUTICAL CO., LTD. (CN) | 2021-07-15 | — | — | US | disclosed |
| US-20210214377-A1 | SYNTHESIS OF PEPTIDE BORATE ESTER COMPOUND AND USE THEREOF | JIANGSU CHIA TAI FENGHAI PHARMACEUTICAL CO., LTD. (CN) | 2021-07-15 | — | — | US | disclosed |
| EP-3805237-A1 | SYNTHESIS AND USES OF PEPTIDE BORATE ESTER COMPOUND | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
| EP-3805237-A1 | SYNTHESIS AND USES OF PEPTIDE BORATE ESTER COMPOUND | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214377-A1 | SYNTHESIS OF PEPTIDE BORATE ESTER COMPOUND AND USE THEREOF | SEM1, VIP, PSMB11 | APLNR 2578/4885DPP7 235/4885ALDH1A1 4592/4885 |
| US-11542283-B2 | Synthesis of peptide borate ester compound and use thereof | SEM1, VIP, PSMB11 | APLNR 2578/4885DPP7 235/4885ALDH1A1 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.